NCT06291961 - A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2025

Conditions

Beta-Thalassemia Major

Interventions

GENETIC

CS-101 injection

Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique

Trial Locations (3)

RECRUITING

The First Affiliated Hospital of Guangxi Medical University, Nanning

RECRUITING

Children's Hospital of Fudan University, Shanghai

RECRUITING

Ruijin Hospital Shanghai JiaoTong University School of Medicine, Shanghai